The United States Patent and Trademark Office has provided a new patent for OSE Immunotherapeutics’ Tedopi, a vaccine for cancer.

Tedopi is intended for human leucocyte antigen (HLA)-A2 positive patients following secondary resistance to treatment with PD-1/PD-L1 immune checkpoint inhibitor. 

The latest patent will boost the vaccine’s value proposition and offers protection in the country until 2037.

Tedopi is an immunotherapy that stimulates tumour-specific T-cells. It is the most advanced asset of the company. 

The Phase III Atalante 1 clinical trial of the vaccine generated positive data in patients with non-small cell lung cancer with secondary resistance following the failure of treatment with a checkpoint inhibitor.

Japan has also granted a patent for the vaccine in the same targeted population.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

OSE Immunotherapeutics CEO Nicolas Poirier stated: “We are very pleased to expand our patent portfolio internationally with this new US patent strengthening the protection rights for Tedopi in the significant US market. 

“This patent represents an additional milestone in the product’s clinical development based on the first Phase III positive results in non-small cell lung cancer after checkpoint inhibitor escape in secondary resistance.

“These data show a significant overall survival benefit, an improved quality of life and a better safety profile versus chemotherapy. The next confirmatory Phase 3 trial under preparation in second-line treatment will address the same high unmet medical need. Tedopi presents a differentiated mechanism of action activating tumour-specific T cells after acquired resistance of immune checkpoint inhibitor.” 

OSE Immunotherapeutics focuses on developing products in the immuno-oncology and immuno-inflammation fields.

Its clinical pipeline comprises Tedopi, OSE-279, OSE-127, FR-104/VEL-101 and OSE-172/BI 765063.